Thursday 27th January 2022, 5 p.m. CET | 11 a.m. EST

Biopharma Dealmaking in 2022: Trends & Forecasts

2021 was a busy year in biopharma dealmaking. There were billion-dollar deals, a flood of funding, increased early-stage partnering, and new therapeutic areas and platforms coming online. Now, armed with record amounts of cash and funding, 2022 is poised to be another remarkable year for life science companies in general and partnering specifically.

Join Chris Dokomajilar, CEO at DealForma, and Echo Zhang, Product Strategy Director at Inova, as they discuss:

  • Partnering and dealmaking trends in 2021
  • What lies ahead in 2022

Join us and get expert insights from our panelists:
Chris Dokomajilar
Founder & CEO
DealForma
Echo Zhang
Product Strategy Director
Inova